FDA Approves Ivacaftor Drug for Cystic Fibrosis : More Patients to Benefit

FDA Approves Ivacaftor Drug for Cystic Fibrosis : More Patients to Benefit

Health In Focus
RSS Email Print This Page Comment bookmark
Font : A-A+

  • The new drug ivacaftor addresses the problem of chloride transport within the cells of patients with cystic fibrosis
  • It is used in the treatment of patients with specific mutations in the CFTR gene
  • The expansion of its use from 10 to 33 mutations will ensure that more patients will receive the benefits of this drug
The cystic fibrosis drug ivacaftor has been approved by the US Food and Drug Administration (FDA) to treat patients with mutations that were not approved earlier, thus making the medication accessible to more patients with the disease.
FDA Approves Ivacaftor Drug for Cystic Fibrosis : More Patients to Benefit

Cystic fibrosis is a genetic disorder more common in Caucasians and caused by a mutation in a gene referred to as the CFTR gene (Cystic Fibrosis Transmembrane conductance Regulator gene). The condition is inherited in an autosomal recessive pattern, which means that both parents should have the defective gene for the condition to be passed on to the children.

Cystic fibrosis results in the accumulation of sticky mucus in several organs of the body, especially the lungs, pancreas and liver, resulting in reduced functioning of these organs. The sweat in these patients is typically salty. Treatments are aimed at reducing the symptoms, and preventing and treating complications. Newer treatments, including gene therapy, are being explored to improve the quality of life and the life span of patients affected by this genetic disorder.

The new drugs ivacaftor and the ivacaftor/lumacaftor combination address the basic problem of cystic fibrosis. They improve the function of the chloride channel that is defective in patients with cystic fibrosis and thereby improve the condition.

Ivacaftor first received approval for the treatment of cystic fibrosis due to a specific G551D mutation in the CFTR gene in 2012. It is, however, not effective in those with the F508 mutation in the CFTR gene, which is the more common mutation in cystic fibrosis. The patient can find out what type of mutation they have based on available laboratory tests for the purpose.

Ivacaftor has to be taken in tablet form or as granules twice a day with a fatty meal. Side effects include symptoms of an upper respiratory tract infection like sore throat, nasal or sinus congestion, or runny nose, headache, stomach ache, diarrhea, rash and dizziness.

With the recent FDA approval to increase the spectrum of cystic fibrosis patients who can receive ivacaftor, from 10 mutations to 33, the benefit of the drug will reach around 900 more people suffering from the genetic disorder in the United States. The additional approval is based on laboratory studies and not on clinical trials since the latter are not feasible given the relatively small number of patients suffering from the disease.

References :
  1. FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis - (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm559212.htm)

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

Drug Toxicity Signature Drug Toxicity Genetic Testing of Diseases Cystic Fibrosis Drugs Banned in India Fibroscan for Fatty Liver Cirrhosis and Fibrosis Retroperitoneal Fibrosis / Ormond´s Disease 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive